采样时机对急性心肌梗死患者亚临床甲状腺功能障碍诊断及死亡率的影响:ThyrAMI1研究
本研究纳入1806例急性心肌梗死患者,入院时检测甲状腺功能,TSH异常者至少一周后复查。采用统一TSH参考区间时,亚临床甲减患病率为17.2%,亚临床甲亢为1.2%。
要点
- 急性心梗患者亚临床甲减患病率17.2%,亚临床甲亢1.2%。
- 采样时机影响亚临床甲状腺功能障碍诊断风险,亚临床甲减风险午夜至清晨最高。
- 使用时间段特异性TSH参考范围时,亚临床甲减患者死亡风险显著增加。
核心结论
- 采样时机影响急性心肌梗死患者亚临床甲减的诊断和预后,忽略采样时机会导致系统性误分类并丢失其对死亡率的可测量影响。
研究设计与样本
- 前瞻性研究,纳入2014年12月至2016年12月间1806例急性心肌梗死患者,入院时检测甲状腺功能,TSH异常者至少一周后复查,随访至2018年6月。
主要发现
- 使用统一TSH参考区间时,亚临床甲减患病率为17.2%(n=311),亚临床甲亢为1.2%(n=22)。
- 完全校正模型中,亚临床甲减诊断风险在00:01至06:00最高、12:01至18:00最低(趋势P<.001);亚临床甲亢风险在12:01至18:00最高、00:01至06:00最低。
- 初始采样时间与后续维持亚临床甲减状态的风险相关。
- 使用统一TSH参考区间时,亚临床甲减患者死亡率未升高;使用时间段特异性TSH参考范围时,亚临床甲减患者死亡风险显著升高,HR(95%CI)为2.26(1.01-5.19),P=.04。
临床怎么用
- 在急性心肌梗死患者中诊断亚临床甲状腺功能障碍时,应考虑采样时机对TSH参考区间的影响,避免系统性误分类。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: The objective of this study was to determine the impact of blood sample timing on the diagnosis of subclinical thyroid dysfunction (SCTD) and mortality in patients with acute myocardial infarction (AMI). PATIENTS, DESIGN, AND MAIN OUTCOME MEASURES: Patients with AMI had thyroid function evaluated on admission between December 2014 and December 2016 and those with abnormal serum thyrotropin (TSH) had repeat thyroid function assessed at least a week later. The association between sample timing and SCTD was evaluated by logistic regression analysis. Secondary outcomes were confirmation of SCTD on repeat testing and all-cause mortality up to June 2018. RESULTS: Of the 1806 patients [29.2% women, mean (± standard deviation) age of 64.2 (±12.1) years] analyzed, the prevalence of subclinical hypothyroidism (SCH) was 17.2% (n = 311) and subclinical hyperthyroidism (SHyper) was 1.2% (n = 22) using a uniform TSH reference interval. The risk of being diagnosed with SCTD varied by sample timing in fully-adjusted models. The risk of SCH was highest between 00.01 and 06.00 hours and lowest between 12.01 and 18.00 hours, P for trend <.001, and risk of SHyper was highest between 12.01 hours and 18.00 hours and lowest between 00.01 hours and 06.00 hours. Furthermore, time of the initial sample was associated with the risk of remaining in a SCH state subsequently. Mortality in SCH patients was not elevated when a uniform TSH reference interval was utilized. However, when time period-specific TSH reference ranges were utilized, the mortality risk was significantly higher in SCH patients with HR (95% CI) of 2.26 (1.01-5.19), P = .04. CONCLUSIONS: Sample timing impacts on the diagnosis and prognosis of SCH in AMI patients. If sample timing is not accounted for, SCH is systemically misclassified, and its measurable influence on mortality is lost.
引用
- Razvi S, Leng O, Jabbar A, et al. Sample Timing, Diagnosis of Subclinical Thyroid Dysfunction and Mortality in Acute Myocardial Infarction: ThyrAMI1 Study. J Clin Endocrinol Metab. 2020. PMID: 31769839. doi:10.1210/clinem/dgz143
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。